Akèy › Leukemi limfoblastik ak limfom selil T prekursè
Etid klinik pou Leukemi limfoblastik ak limfom selil T prekursè ap rekrite nan Etazini
23 etid pou Leukemi limfoblastik ak limfom selil T prekursè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX8 etid
- New York City, NY6 etid
- Columbus, OH5 etid
- Philadelphia, PA4 etid
- Washington, DC4 etid
- Boston, MA3 etid
- Staten Island, NY3 etid
- Edison, NJ3 etid
- St. Louis, MO3 etid
- Baldwin Park, CA3 etid
- East Norwalk, CT3 etid
- Queens, NY3 etid
- New Rochelle, NY3 etid
Pa eta
- Colorado3 etid
- Florid3 etid
- Kalifòni5 etid
- Massachusetts3 etid
- Missouri3 etid
- New Jersey3 etid
- New York7 etid
- North Carolina3 etid
- Ohio6 etid
- Pennsylvania5 etid
- Tennessee3 etid
- Texas8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 30, 2026 · NCT06904066A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Ap rekriteFaz 2
6 Months · Tout sèks · Mizajou Sep 28, 2026 · NCT06514794Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT04301076Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Ap rekriteFaz 2
1 Month – 21 Years · Tout sèks · Mizajou Sep 18, 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Ap rekriteFaz 1
Jiska laj 39 · Tout sèks · Mizajou Sep 11, 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Ap rekriteFaz 1
Laj 12 a 30 · Tout sèks · Mizajou Aug 12, 2026 · NCT07513129Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Aug 11, 2026 · NCT03081910Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Aug 10, 2026 · NCT06390319Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Jul 15, 2026 · NCT00501826Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Ap rekriteFaz 1
Laj 0 a 29 · Tout sèks · Mizajou Jul 7, 2026 · NCT06934382Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou May 18, 2026 · NCT07220993Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 14, 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 30, 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.